Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 76.33

-1.1%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2014)	6/3/1998 1:06:00 AM
From: marc ultra	Read Replies (1) of 4676

For the first time I'm really getting concerned at least in the intermediate term of ISIP's prospects. We know that fomvirisen is likely to be a meager revenue generator and now that FDA advisory panel is recommending approval of CNTO's Crohn's drug there is a good chance by the time 2302 is proven CNTO's drug may have become widely accepted making 2302 for Crohn's an afterthought. We really don't know how well 2302 will be for other indications since no impressive early trials like we had for Crohn's. Cancer drugs while interesting have no evidence at this point of being blockbusters. Arguments refuting my concerns are welcome Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next